Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI + Cyclophosphamide Prior to Cilta-cel for Multiple Myeloma With Impaired Renal Function
NCT06623630Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Washington University School of Medicine. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06623630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623630.